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Based on adeno-associated virus derived plasmid construct that are able to synthesize in cells antisense RNAs
directed against key genes of HIV. Gematopoietic human cells carrying the created structure, acquired re-
sistance to HIV infection, as evidenced by the reduction in infectious titer of HIV in cell culture. The resulting
system of intracellular resistance to retrovirus can be seen as a model of gene therapy of AIDS.
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The development of themethods of sequencing and artifi-
cial synthesis of nucleic acids, the discovery of the en-
zymes of restriction and reverse transcription, the elabo-
ration of the technology of polymerase chain reaction
as well as the discovery of the natural mechanism of an-
tisense regulation of gene expression played a critical
role in the radical changes in the possibilities of mole-
cular biology to solve themost urgent problem of the li-
fe sciences – targeted regulation of gene expression.
Scientific and practical facilities in solving this prob-
lem have become goal-oriented and developed in two
directions: artificial synthesis of antisense oligonucleo-
tides and the development of systems of intracellular
biosynthesis of antisense RNA-transcripts, complemen-
tary to specific mRNA sites of the selected target gene.
Due to the discovery of catalytic properties, remarkable
for a specific class of RNA molecules, called ribozy-
mes, we witnessed the formation of a new branch of the
latter trend – the elaboration of molecular constructions
for intracellular synthesis of ribozymes, capable of cut-
ting RNA-transcripts, against which they were direc-
ted. Extremely high specificity of the ribozymes activi-
ty, conditioned by the sequence of as few as several nuc-
leotides, provided the researchers with another effici-
ent instrument of regulating the expression of harmful or
undesired genes. Taking into account the possibilities
and promising results of new approaches to the regula-
tion of gene expression, numerous scientists, searching
for the ways to control viral infections, turned to the me-
thods of creating intracellular antiviral immunity using
antisense RNA (asRNA) and ribozymes.We have contri-
buted our efforts thereto, working in the framework of the
program of the National AIDS Prevention Committee.
The common strategy, developed during several
years of using asRNA to inhibit the reproduction of viru-
ses, foresaw some general rules of selecting the target
gene within the whole viral genome [1, 2]. Both the
theory and experience proved that in the majority of ca-
ses the efficiency of asRNA in blocking a corresponding
mRNAdepends on their molar ratio in the cell during the
time of their expression [2, 3]. Thus, the target in the
cell has to be low-tracing, to have the possibility of crea-
ting the excess of antisense transcripts compared to co-
ding viral mRNA. Therefore, it is reasonable to direct
asRNAs to early viral genes, coding for the regulatory
factors, mRNA-copying ability of which is insignifi-
cant. It provides better chances to acquire the excess of
asRNA and to affect the kinetics of its interaction with a
target mRNA for the benefit of forming a sense–anti-
sense hybrid.
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The computerized analysis of published sequences
of many HIV-1 isolates allowed selecting another area –
Tat-Rev exon with flanks, where the reading frames of
early regulatory and late structural viral proteins over-
lap – as a target for antisense effect. The defined region
of HIV-genome encodes the regulatory proteins, vital
for productive virus infection and key genetic signals,
and is conservative for the majority of HIV-1 isolates.
The next step in constructing a gene of asRNA was
the selection of the promoter to direct its synthesis in the
cell. It was decided that it would be reasonable to imple-
ment the principle of reverse connection between the an-
tisense gene andHIV-1 genome for the expression of an-
tiviral antisense transcripts. It is possible if the synthesis
of asRNA is directed by HIV promoter, activated by
early products of HIV-genome, namely, transactivator
Tat. In this case the level of asRNAs expression would
depend on the expression of the most important HIV-1
genes (Fig. 1), i. e. the cell should have the state of ba-
lanced counteraction, where asRNAs control the level
of key viral products at the pre-threshold level and thus
block the transition of the viral infection into the pro-
ductive phase. This principle of applying the transcrip-
tional system of HIV promoter was successfully used by
other laboratories [4] for intracellular expression of so-
me genes with anti-HIV activity or super expression of
different recombinant genes with non-specific antiviral
activity (interferons, etc.). Pursuant to the determined
properties there was a designed non-enhancer HIV pro-
moter with triple tandem of SP-1 elements of transcrip-
tional factors and TAR-element for the interaction with
HIV-transactivator Tat. In a non-transformed cell this
promoter is stronger than the native one, as it is not a
subject to the effect of negative cellular factors. The
sequence of the created recombinant promoter demonst-
rated the correspondence to the transcriptional HIV unit
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Fig. 1. The scheme of
intracellular regulation of
transcription of antisense
RNA against Tat/Rev
mRNA HIV-1 and the
mechanism of negative
feedback from regulatory
genes of the virus. Upper
part – antisense gene;
bottom – genome of HIV-1
provirus [4]
with ÒÀÒÀ-initiator, the main elements of transcrip-
tion initiation SP-1- and TAR-element (Fig. 2).
The vector, selected by us, was human adeno-asso-
ciated virus (AAV), the advantages of which were high-
lighted in a number of publications [5, 6]. Besides, the
projective vector should contain a selective marker for
transfected cells. This selected vector was a traditional-
ly used resistance gene to aminoglycoside antibiotics
nåîr, which allows selecting transfected cells in the me-
dium with antibiotic G418. The own AAV transcrip-
tion terminator of viral vector was used to terminate
the transcription of asRNA.
The created antisense construction pHIV-as-neo is
presented in Fig. 3. The basis of the molecular vector is
AAV genome without genes of structural proteins,
which is cloned into the gene àmðr of plasmid pBR322.
The place of genes of structural proteins in AAV-vec-
tor is taken by the cloned selective gene of neomycin
phosphotransferase nåîr and HIV-antisense gene. Du-
ring the transfection of this plasmid into cells the DNA
sequence, flanked by terminal repeats (ITR AAV),
should be stably integrated into the chromosome of hu-
man hematopoietic cells. The transcription of asRNA
from this recombinant construction is provided by the
cloned and enhancer-free HIV-1 promoter.
The sequence of the cloned fragment demonstrated
that it corresponds to the transcriptional HIV unit with
TATA-initiator, the main elements of SP-1 transcrip-
tion initiation and TAR-element, the efficiency of which
can be enhanced by the protein Tat via TAR-element. In
this construction the constitutive expression is enhan-
ced by the promoter Òn5, located above. Therefore,
asRNA is synthesized as a constituent of mRNA of gene
nåî in its 5'-non-coding part. Besides the antisense me-
chanism of inhibiting HIV replication, ensuring the
created antisense gene, there is an expectation of the ad-
ditional impact on HIV from Rep-protein of AAV,
which has already been reported in scientific literature
[7–10], and from TAR-element, also mentioned in the
literature as an executive link of the mechanism of HIV
replication block, called TAR-decoy [11, 12].
The study on the sensitivity of intact hematopoietic
cells of human embryo liver to HIV-infection demonst-
rated that only in two (samples 7 and 10) out of 25 in-
vestigated samples of cells, isolated from different emb-
ryos, the synthesis of antigen ð24 (Fig. 4, A) and the ti-
ters of the infectious virus (Fig. 4, B) were compatible
to these indices of viral reproduction in the standard
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Fig. 3. The scheme of vector pHIV-as-neo, expressing anti-HIV asRNA
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Fig. 2. Transcriptional unit of
the created antisense gene:
165-nucleotide fragment –
enhancer-free promoter LTR
HIV-1 with binding sites for
transcriptional factors SP-I,
ÒÀÒÀ-box and TAR-element
of HIV promoter; + 1 – start of
transcription; 386-nucleotide
fragment – sequence of HIV
genome, cloned in antisense
orientation relative to HIV
promoter [4]
cell cultureÌÒ-4, traditionally used in the experiments
of HIV isolation and titration. In our studies the infec-
tious titer of the virus in sample 12 was lower than the
rest, while no virus presence was detected in sample 11,
which testifies to either considerable or complete resis-
tance of these cells to HIV-infection. Infectious indices
were rather high in the cultures of cells from the rest of
embryo samples – sometimes exceeding by 2 lg ID50 the
HIV titer in cells ÌÒ-4 (Fig. 4, B, samples 2 and 6).
Numerous references demonstrate that along with
typical tempo of HIV-infection progress some patients
had a rapid transition to AIDS stage, for others this pro-
cess was very slow, and a small percentage stayed heal-
thy, regardless of previous, often repeated, infection in-
cidents. Different indices of HIV-resistance for diffe-
rent samples of hematopoietic cells, revealed in our ex-
periments, are somewhat similar to the distribution of
clinical infection rates, although one should not expect
their absolute coincidence as our experiment in vitro la-
cked the components of immune protection of the mac-
roorganism. However, one can state that the data, ob-
tained on the cellular level, were indirect testimony
to the existence of natural mechanisms of resistance to
HIV-infection.
The data of virologic studies are presented in Fig. 5.
In the chosen cultivation conditions (with antibiotic
G418) the cells, transfected with vector plasmid pDL52-
91neo, having the sequences of Rep-protein ÀÀV wi-
thout the antisense fragment, demonstrated the inhibi-
tion of HIV reproduction by 15–25 %. The effect of in-
hibiting virus replication in this experiment (virus cont-
rol) may be conditioned by the activity of Rep-protein
ÀÀV. There was no significant impact on HIV-infec-
tion in the control experiment, where the cells were
transfected with the plasmid, containing only terminal
repeats of ÀÀV (i. e. incapable of synthesizing Rep-pro-
tein ÀÀV). This is indirect evidence to the data of [7–
10] on the capability of AAV-specific Rep-protein to
inhibit HIV reproduction.
The reduction in antigen production by 66% and the
infectious titer of HIV by 99 %, compared to the cultu-
res without antisense constructions, was observed while
determining the virus titer and its production of antigen
p24 in the population of cells, transfected with antisen-
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Fig. 5. The effect of anti-
sense vector construction on
HIV reproduction in hema-
topoietic cells: A – in the
presence of antibiotic G-418;
B – without the antibiotic (a
– non-transfected cells; b –
cells, transfected with
vector construction pDL52-
91neo; c – cells, transfected
with antisense vector con-
struction pHIV-as-neo) [4]
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Fig. 4. HIV-1 reproduction
in hematopoietic cells of
human embryo liver: 1–12 –
numbers of cultures from
different embryos; 13 – cells
of MT-4 line. Typical data
are presented for illustration
[14]
se plasmid and cultivated in the presence of selective
antibiotic. The reduction in the infectious titer of the
virus (by two orders) is a decisive index of inhibitory ef-
fect, but the synthesis rate of virus-specific protein p24
in our experiments could be estimated with less optimism.
However, the analysis of data obtained testifies to the ab-
sence of grossmistakes both in the establishment of genetic
constructions and in their testing. The arguments for the
latter statement can be explained as follows.
The most decisive result in favor of anti-HIV effi-
ciency of the created antisense construction is the index
of significant reduction of the titer of the infectious
virus in the cells, transfected by it. The antisense RNA
transcripts in the elaborated system are directed tow-
ards the inhibition of the expression of regulatory Tat
and Rev-proteins of HIV, which, as stated above, are
critical constituents of the virus replication cycle.
The traditional and common method of detecting
viral infection by the level of protein p24 synthesis
during the testing of our construction is not sufficient to
reflect the actual picture of infectious process, as it does
not relate to the biosynthesis mechanism of this protein
directly. Protein ð24 is the product of gene gag; it is a
structural group-specific protein, building the envelope
of HIV nucleoid, synthesized in large quantities.
The realization of functions of our construction oc-
curs in response to HIV appearing in the cell, its early
product – protein Tat, in particular. This protein activa-
tes the transcription of the viral genome, which results
in the launch of synthesis of other viral proteins, inclu-
ding the products of gene gag. The transcription of HIV
genome stops with accumulating antisense RNA in the
cell, but the synthesis of ð24 goes on RNA-transcripts,
which occurred in the initial period of viral infection un-
til their complete degradation. As the assembly of viri-
ons takes place at the later stages of the infectious pro-
cess and depends on the presence of all the structural
components, the synthesis of which depends on free
functioning of regulatory mechanisms, the latter are da-
maged by antisense effect and it impacts the formation
of infectious viral particles.
In our opinion, this progress is reflected by our
data: the indices of the yield of mature (infectious) HIV
in the cells, transfected by antisense construction, were
determined in smaller amounts than the indices of the
content of virus-specific antigen p24.
It should be mentioned that in case of cultivation wi-
thout any selective pressure the there was not registered
significant inhibition of virus reproduction in the cells,
transfected by both antisense plasmid and control vec-
tor plasmids (Fig. 5, c). It is conditioned by the fact that
only 3–5 % of populations of infected cells are ensured
by the antisense intracellular immunity. The major part
of population cells is not transfected and in the absence
of anti-metabolite, aminoglycoside antibiotic, they pre-
serve the normal level of viability and normal sensiti-
vity to HIV-infection. In the conditions of selective
pressure of G418 some cells perish, metabolism is inhi-
bited, so, these conditions are either hardly suitable for
the support of viral reproductive cycle or this process is
completely impossible.
Taking into consideration the achieved positive re-
sults of inhibiting in vitro replication of HIV in human
hematopoietic cells with antisense vector constructions,
one might assume that once these cells are transfused to
the patient with AIDS, they will take on the functions of
immune protection of the organism. One could also as-
sume that once the blood flow is filled with HIV-re-
sistant descendants of transplanted stem hematopoietic
cells and predecessor cells, the blood of the HIV-in-
fected recipient would gradually clear from the agent.
Taking into account the presence of viral protein
ð24 in transfected cells and some others, as well as a tra-
ce level of the formation of mature virions, one might
expect that during this controlled infectious process the
organism will produce antiviral antibodies, which will
promote the formation of immune protection. If the as-
sumed effects take place in the patient’s organism, it
could be possible that transplantation of HIV-resistant
hematopoietic cells will prolong his life or at least alle-
viate his suffering. The results of clinical trials of our
system for gene therapy of AIDS could confirm (or
demolish) the abovementioned assumptions.
Therefore, our investigations resulted in the elabo-
ration of the gene therapy system for AIDS, which is
composed of human hematopoietic cells, protected
from HIV by intracellular immunity. This immunity is
based on the molecular genetic construction, built using
AAV-vector, containing an LTR-derivative HIV-trans-
criptional unit, capable of induced synthesis of asRNA,
directed against key HIV genes – tat and rev. The
induction of synthesis of antisense transcripts is perfor-
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med by HIV-specific proteins in the early period after
the intervention of the agent into the cell. Our antisense
system can be used for further pre-clinical trials.
The results, obtained while conducting the inves-
tigations, were used in PhD and doctorate theses, high-
lighted in 6 publications and presented at 3 scientific
forums.
À. Ä. Øâåä, Î. Ï. Êóõàðåíêî
Ñòâîðåííÿ ñèñòåìè ãåííî¿ òåðàï³¿ ÑÍ²Äó
íà îñíîâ³ àíòèñåíñîâèõ ÐÍÊ
Ðåçþìå
Íà áàç³ àäåíîàñîö³éîâàíîãî â³ðóñó îòðèìàíî ïëàçì³äíó êîíñòðóê-
ö³þ, çäàòíó äî ñèíòåçó â êë³òèí³ àíòèñåíñîâèõ ÐÍÊ, ñïðÿìîâà-
íèõ ïðîòè êëþ÷îâèõ ãåí³â Â²Ë. Ãåìîïîåòè÷í³ êë³òèí³ ëþäèíè, ùî
íåñóòü â ñîá³ ñòâîðåíó êîíñòðóêö³þ, íàáóâàþòü ñò³éêîñò³ äî
Â²Ë-³íôåêö³¿, ùî çàñâ³ä÷óº çíèæåííÿ ³íôåêö³éíîãî òèòðó Â²Ë ó
êóëüòóð³ êë³òèí. Îäåðæàíó ñèñòåìó âíóòð³øíüîêë³òèííî¿ ðåçè-
ñòåíòíîñò³ äî ðåòðîâ³ðóñó ìîæíà ðîçãëÿäàòè ÿê ìîäåëü ãåíî-
òåðàï³¿ ÑÍ²Äó.
Êëþ÷îâ³ ñëîâà: Â²Ë-ÑÍ²Ä, àäåíîàñîö³éîâàíèé â³ðóñ, àíòèñåí-
ñîâ³ ÐÍÊ, ãåííà òåðàï³ÿ, ãåìîïîåòè÷í³ êë³òèí³ ëþäèíè.
À. Ä. Øâåä, À. Ï. Êóõàðåíêî
Ñîçäàíèå ñèñòåìû ãåííîé òåðàïèè ÑÏÈÄà íà îñíîâå
àíòèñìûñëîâûõ ÐÍÊ
Ðåçþìå
Íà áàçå àäåíîàññîöèèðîâàííîãî âèðóñà ïîëó÷åíà ïëàçìèäíàÿ êîíñò-
ðóêöèÿ, ñïîñîáíàÿ ñèíòåçèðîâàòü â êëåòêå àíòèñìûñëîâûå ÐÍÊ,
íàïðàâëåííûå ïðîòèâ êëþ÷åâûõ ãåíîâ ÂÈ×. Ãåìîïîåòè÷åñêèå
êëåòêè ÷åëîâåêà, íåñóùèå ñîçäàííóþ êîíñòðóêöèþ, ïðèîáðåòà-
þò óñòîé÷èâîñòü ê ÂÈ×-èíôåêöèè, î ÷åì ñâèäåòåëüñòâóåò ñíè-
æåíèå èíôåêöèîííîãî òèòðà ÂÈ× â êóëüòóðå êëåòîê. Ïîëó÷åí-
íóþ ñèñòåìó âíóòðèêëåòî÷íîé ðåçèñòåíòíîñòè ê ðåòðîâèðóñó
ìîæíà ðàññìàòðèâàòü êàê ìîäåëü ãåíîòåðàïèè ÑÏÈÄà.
Êëþ÷åâûå ñëîâà: ÂÈ×-ÑÏÈÄ, àäåíîàññîöèèðîâàííûé âèðóñ,
àíòèñìûñëîâûå ÐÍÊ, ãåííàÿ òåðàïèÿ, ãåìîïîåòè÷åñêèå êëåòêè
÷åëîâåêà.
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